Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07613294 · ClinicalTrials.gov registry record · Phase 3
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
A Phase 3 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 252
- Enrollment target
NCT07613294 is a Phase 3 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 252 participants.
The verdict
NCT07613294, a Phase 3 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 252 participants
- Enrollment target
Study Summary
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the heart's vessels using an imaging technology known as Coronary Computed Tomography Angiography (CCTA) in adults who have high levels of Lp(a). Participation will last about 120 weeks.
Interventions
- DRUG Placebo
- DRUG Lepodisiran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2026-06-02 |
| Est. Completion | 2029-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07613294
The ClinicalTrials.gov registry entry for NCT07613294 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07613294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07613294 about?
NCT07613294 is a clinical study titled "A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk". Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type of plaque in the hea...
What is the current status of trial NCT07613294?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 252 participants. The study started on 2026-06-02. Estimated completion is 2029-04.
What interventions are being tested in trial NCT07613294?
The interventions under investigation include: Placebo (DRUG), Lepodisiran (DRUG).
Who is sponsoring clinical trial NCT07613294?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.